The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LI.a

Left or biventricular dysfunction/failure

Publications

Chang WT, Chen PW, Lin HW, Lin SH, Li YH

Risks of trastuzumab-related cardiotoxicity in breast cancer patients in Taiwan.

ESC heart failure 2021 Dec;8;5149-5158 — 2021 Dec — 5149-5158

Tanaka S, Ikari A, Nitta T, Horiuchi T

Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors.

Oxford medical case reports 2017 Jul;2017;omx038 — 2017 Jul — omx038

Ürun Y, Utkan G, Yalcin B, Akbulut H, Onur H, Oztuna DG, ?enler FC, Demirkaz?k A, ?çli F

The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.

Experimental oncology 2015 Mar;37;53-7 — 2015 Mar — 53-7

Maxwell CB, Jenkins AT

Drug-induced heart failure.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2011 Oct 01;68;1791-804 — 2011 Oct 01 — 1791-804

Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK

Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.

Mayo Clinic proceedings 2008 Feb;83;197-203 — 2008 Feb — 197-203

Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Nov 01;23;7820-6 — 2005 Nov 01 — 7820-6